cyrilzakka/clinical-trials huggingface dataset:
Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery

This study is to assess the usability and acceptability of a digital food consumption diary as part of the perioperative management of gastrointestinal oncology patients and to evaluate the impact of a digital food diary on adherence to dietician-recommended plan and on quality recovery, using a commercially available smart phone application.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of gastrointestinal (GI) cancers confirmed by tissue diagnosis and/or clinical presentation as judged by the treating physician
* Candidate for curative-intent surgery
* Participants will be eligible for participation regardless of degree of malnutrition (as determined at pre-operative dietary consultation)
* Own a smartphone with iOS or Android operating systems with WiFi or 3G/4G connection
* Willingness to download the Livestrong.com MyPlate Calorie Tracker onto a personal smart phone with assumption and responsibility for individual data usage, and creation of login for website data extraction
* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Sufficient English language proficiency to execute study tasks

Exclusion Criteria:

* Participants with tube feeds and/or need for parenteral/enteral nutrition
* Participants not willing to download or utilize the commercially available weight monitoring application
Epidemiology of Conjunctivitis in the Emergency Department

Epidemiology of Conjunctivitis in the Emergency Department of a Reference Ophthalmological Hospital in Goiânia.

The purpose of this study was to determine the epidemiology of ocular emergencies in a Reference Ophthalmological Hospital in Goiânia, with emphasis on acute infectious conjunctivitis, morbidity with a higher incidence in this Service. It aims to delineate the main etiologies found among infectious conjunctivitis and to compare them with those found in several other reference services in Ophthalmology.

Eligibility Criteria:
Inclusion Criteria:

* All those patients who were submitted to a initial care performed by the First Year Resident (R1) of the Hospital and who were admitted during the period described.

Exclusion Criteria:

* The patients who were admitted in the Emergency Department outside this period
* The patients who were not attended by a First Year Resident (R1)
* The patients who did not have all the data filled in the medical record
* The patients who needed to return, being attended in the hospital more than once.
Evaluation of the Effect of Adding Dexamethasone to 2% Lidocaine

This randomized, double-blind clinical trial aimed at the evaluation of the effect of adding dexamethasone to 2% lidocaine, given as inferior alveolar nerve block in the endodontic management of symptomatic irreversible pulpitis. One hundred and twenty four patients received one of the three IANB injections before the endodontic treatment: 2% lidocaine with 1:80 000 epinephrine; 2% lidocaine with 1:80 000 epinephrine mixed with 2mg dexamethasone; and plain 2% lidocaine mixed with 2mg dexamethasone. The anesthetia was considered successful if the patients experienced no pain or faint/weak/mild pain during root canal access preparation and instrumentation (HP VAS score \<55 mm). The effect of intraligamentary injections on maximum heart rates was also recorded.


Eligibility Criteria:
Inclusion Criteria:

* absence of any periapical radiolucency on radiographs, except for a widened periodontal ligament
* active pain in a mandibular molar
* prolonged response to cold testing with an ice stick and an electric pulp tester
* vital coronal pulp on access opening and ability to understand the use of pain scales

Exclusion Criteria:

* a history of known or suspected drug abuse
* history of active peptic ulcer within the preceding 12 months
* history of bleeding problems or anticoagulant use within the last month
* known allergy, sensitivity, or contraindications to any opioid or nonopioid analgesic including aspirin or NSAIDs
* patients who had taken NSAIDs within 12 h before administration of the study drugs
* patients who were pregnant or breast-feeding
Dexamethasone Versus Dexmedetomidine as Adjuvants for Nerve Blocks

When used as perineural (PN) adjuvants to local anesthetics (LAs), dexamethasone (DX) and dexmedetomidine (DXD) have been well documented to prolong the duration of peripheral nerve blocks. These drugs have important differences in terms of cost and safety profiles. This randomized controlled trial (RCT) will compare PN DX and PN DXD for ultrasound-guided infraclavicular brachial plexus blocks (ICBs).

Since analgesic and sensory duration can be influenced by factors different to block, motor block duration is the main outcome. The protocol is designed as an equivalency trial and hypothesize that both drugs result in similar durations. The equivalency margin is set at 3 hrs.


Eligibility Criteria:
Inclusion Criteria:

* age between 18 and 75 years
* American Society of Anesthesiologists classification 1-3
* body mass index between 20 and 35

Exclusion Criteria:

* adults who are unable to give their own consent
* pre-existing neuropathy (assessed by history and physical examination)
* coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)
* renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
* hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
* allergy to local anesthetics (LAs)
* pregnancy
* prior surgery in the infraclavicular region
* chronic pain syndromes requiring opioid intake at home
The Benefit of a Deep Cleansing Gel in the Management of Mild to Moderate Truncal Acne

Acne vulgaris is a chronic inflammatory disease, mainly of the face, but also of the trunk. Acne may be caused by internal and external factors. Only a very small amount of data exists concerning truncal acne. The condition affects about 9% of the population worldwide, with 50% of subjects with facial acne also presenting with truncal acne. Until recently, clinicians frequently followed the same therapeutic approach as for facial acne, with treatment adherence remaining an issue.

This study assessed assessed the benefit of a cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and Lipo hydroxy acids (LHA) 0.05%, used daily for 84 days in mild to moderate truncal acne.

For this single center, open label, non-randomized exploratory study, 51 subjects with mild to moderate truncal acne were recruited. The study received ethics committee approval. All subjects provided written informed consent. The investigator evaluated the number of inflammatory, non-inflammatory and total lesions at Baseline, Day 42 and 84. Skin barrier function was appraised via the assessment of transepidermal water loss (TEWL) using a Tewameter® (Courage + Khazaka Electronic GmbH, Germany). Safety was assessed by considering the evaluation of clinical signs and reporting of symptoms, and local adverse reactions. Subjects were asked to gently massage the wet skin of the trunk with the product in the morning and evening for at least 30 seconds, and then thoroughly rinse with tempered water and pat dry.

Eligibility Criteria:
Inclusion Criteria:

* above 18 years
* truncal acne

Exclusion Criteria:

- None
Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

The purpose of this study is to see if an investigational drug known as the lidocaine 5% patch is safe and effective in reducing the symptoms of diabetic neuropathy, to examine how topical lidocaine affects the nerve endings, and to determine whether treatment with the lidocaine patch can prevent the potential progression to chronic diabetic neuropathy pain in subjects who did not report pain at the start of the study.


Eligibility Criteria:
Inclusion Criteria:

* Group 1: 18-70 years of age, non-diabetic with no nervous system disease (healthy control group)
* Group 2: 18-70 years of age with Type I or Type II diabetes with significantly painful diabetic neuropathy (VAS \> 40mm at Baseline)
* Group 3: 18-70 years of age with Type I or Type II diabetes with non- painful or insignificantly painful diabetic neuropathy (VAS \< 40mm at Baseline)

Exclusion Criteria:

* History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator
* Allergy to lidocaine
* Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study
* Women who are pregnant, breastfeeding or trying to become pregnant
* History of slow-healing diabetic foot ulcers
* Current skin or soft tissue lesions on the foot that will interfere with application of the lidocaine patch and or skin biopsies
* Subjects taking Class I antiarrhythmics
* HgA1c \> 11%
* Active cancer within the previous two years except treated basal cell carcinoma of the skin
* Co-morbidities that can produce neuropathy
* Subjects taking sodium channel blockers within one week of study treatment and throughout the study
* Subjects taking any other experimental drugs within 30 days prior to Screening Visit (Visit 1)
* Application of lidocaine patch to either foot within two weeks of Screening Visit (Visit 1)
Treatment of High Altitude Polycythemia by Acetazolamide

The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available. After a first preliminary study in 2003 demonstrating the beneficial effects of acetazolamide in reducing hematocrit in these patients, after 3 weeks of treatment, we want to confirm this effect and implement a treatment protocol of 3 month-duration.

Chronic mountain sickness (CMS) is characterized by an excessive number of red cells in the blood of persons living permanently above the altitude of 2,500m. The symptoms of this very incapacitating disease are : headaches, chronic asthenia, digestive troubles, sleep disturbances. The hemoglobin concentration is higher than 21 g/dl of blood. In addition, patients show a pulmonary hypertension of variable degree, as well as a systemic hypertension.

This disease affects essentially males, but women are also concerned after menopause. The evolution of the disease is always very dramatic, towards a cardiac failure and cerebral vascular stroke. The prevalence is between 8% and 15% on the Andean Altiplano . No pharmacological treatment is available.

A preliminary study was performed (Richalet et al. AJRCCM, 2005) that demonstrated the efficiency of acetazolamide (a carbonic anhydrase inhibitor) in reducing the hematocrit and the erythropoetin concentration,and increasing nocturnal oxygen saturation in patients suffering from CMS, after 3 weeks of treatment.

We plan to perform a double-blinded placebo-controlled study to evaluate the efficiency of a 3-month treatment with daily 250 mg acetazolamide to reduce the hematocrit and hemoglobin concentrations and ameliorate the clinical symptoms of 55 patients suffering from CMS and living at high altitude (Cerro de Pasco, Peru).

Eligibility Criteria:
Inclusion Criteria:

* patients with Chronic mountain sickness and Hb \> 21g/dl

Exclusion Criteria:

* patients smokers
* patients with respiratory or cardiovascular or renal disease
Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19

A prospective physiologic study, in participants with COVID-19-related pneumonia requiring supplemental oxygen (standard oxygen therapy or high-flow nasal cannula (HFNC)) less than 24 hours. The investigators assessed the effect of prone position on ventilation inhomogeneity and ventilation/perfusion mismatch by electrical impedance tomography (EIT).

Once enrolled, an EIT dedicated belt containing 16 electrodes was placed around the participant's chest at the fifth or sixth intercostal space and connected it to an EIT monitor (PulmoVista 500; Dräger Medical GmbH, Lübeck, Germany).

Baseline data were collected during supine position (timepoint SP1), including demographic and anthropometric data, a baseline arterial blood gas measurement, and ventilation parameters including type of supplemental oxygen, respiratory rate, fractional concentration of oxygen in inspired air (FiO2). The participants received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter. Subsequently, each participant was helped into the prone position and data collection，end expiratory occlusion and 10% NaCl solution injection were preformed again after approximately 30 min (timepoint PP1). The participant was then encouraged to maintain the prone position for at least 3 h before being helped back into the supine position. Clinical data collection, end expiratory occlusion and injection of a bolus of 10 mL of 5% NaCl solution were repeated again 1 h after resupination (timepoint SP2).

Eligibility Criteria:
Inclusion Criteria:

1. aged 18 to75 years
2. admitted to intensive care unit with a confirmed diagnosis of COVID-19-related pneumonia
3. requiring supplemental oxygen (standard oxygen therapy or high-flow nasal cannula (HFNC)) less than 24 hours,
4. gave written or witnessed verbal informed consent.

Exclusion Criteria:

1. uncollaborative or had an altered mental status,
2. New York Heart Association class above II
3. history of severe chronic obstructive pulmonary disease
4. Contraindications to the use of EIT (e.g., presence of pacemaker or chest surgical wounds dressing) or prone position (as decided by the attending physician)
5. Impending intubation (on the basis of clinical judgment, including clinical and physiological parameters).
Continuous v Bolus Infusion of Cefazolin During Ventral Hernia Repair

Patients undergoing an elective ventral hernia repair will be randomly assigned to receive either bolus infusion or continuous infusion of the cefazolin as the prophylactic antibiotic. The blood concentrations of unbound cefazolin would be measured in their blood samples and the levels compared within the two groups with respect to their minimal inhibitory concentration (MIC) value.

Patients who will be undergoing elective ventral hernia repair will be potential candidates for this study. Once identified, the surgical team will approach the participant for consent and inclusion in the study. On the day of surgery, the subjects will be assigned to either the Bolus Group (CB) or Continuous Infusion Group (CI) according to a randomly generated assignment procedure. During the procedure, the dose of prophylactic Cefazolin will be given an hour before surgery and will be administered in accordance to group assignment. Subjects in the CB will receive bolus infusions of Cefazolin every 4 hours till the end of surgery. Subjects in the CI group will receive an initial bolus injection of Cefazolin followed by a continuous infusion till the closure of skin incision. Blood samples will be taken during surgery at t=0, 15, 30 and 60 minutes and every hour following till the end of surgery or 6 hours (whichever comes sooner)

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years
* Elective open Ventral hernia repair in CDC class one (clean) cases
* Planned operative time greater than 4 Hours
* Planned routine administration of cefazolin for pre-op prophylaxis
* No history of MRSA

Exclusion Criteria:

* Patients unable to give informed consent
* Allergy to cephalosporins
* Pre-existing documented infection or ostomy (class II-IV wounds)
* Received cefazolin within 24 hours before surgery
* Creatinine clearance \< 30 ml/min
* Upstaging of wound class intra-op that results in the administration of additional antibiotics
Effect of Different Drilling Techniques on Primary Stability and Marginal Bone Loss of Extra Short Implants

Our aim in this study is to compare the effects of low-speed drilling surgery technique without irrigation and conventional implant surgery technique with irrigation on extra short implants. The criteria to be taken into consideration when investigating the effect of these techniques on implants are as follows: evaluation of osseointegration at the end of three months, evaluation of marginal bone loss at the end of three months, initial insertion torque values (maximum insertion torque and final insertion torque), ISQ values obtained with a radiofrequency analyzer (Osstel) at the beginning and at the end of three months.


Eligibility Criteria:
Inclusion Criteria:

* There must be toothless space in the maxillary and mandibular posterior region (distal part of the canine in each quadrant).
* The edentulous space should not require additional bone grafting.
* Bleeding areas on probing should be less than 10%
* There should be no pathological periodontal pockets
* Patients who do not smoke or smoke less than 10 cigarettes
* There should be no bruxism
* At least 6 months must have passed since the last tooth extracted from the toothless space where the implant is planned.
* There should be no diabetes.

Exclusion Criteria:

* Having psychological problems
* Smoking more than 10 cigarettes
* Alcohol and drug use
* Pregnancy
Non-alcoholic Fatty Liver Disease and Its Treatment

Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A major unanswered question concerns the potential ability of DPP-4I to improve intrahepatic lipid (IHL) content in nonalcoholic fatty liver disease (NAFLD) patients. The aim of this study was to evaluate the effects of sitagliptin on IHL in NAFLD patients.

A prospective, 24-week, single-center, open-label, comparative study enrolled 68 Chinese NAFLD patients with T2DM. Subjects were randomly divided into 4 groups: control group who did not take medicine (14 patients); sitagliptin group who received sitagliptin treatment (100mg per day) (17 patients); metformin group who received metformin (500mg three times per day) (17 patients); and sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients). IHL, physical examination (waist circumstances, WC; body mass index, BMI), glucose-lipid metabolism (fasting plasma glucose, FPG; hemoglobin A1c, Hb1A1c; triglycerides; cholesterol; alanine aminotransferase, ALT; aspartate aminotransferase, AST) were measured at baseline and at 24 weeks.

Eligibility Criteria:
Inclusion Criteria:

* age 30-70 years old
* fulfillment of the diagnostic criteria for T2DM by WHO in 1999 (HbA1c ranged from 7% to 10%, FPG \< 11 mol/l, 2-hour blood glucose postprandial \< 20mmol/l)
* Fulfillment of the diagnostic criteria for NAFLD according to the guidelines of the Chinese Medical Association in 2010. The IHL content was measured by using 1H-magnetic resonance spectroscopy (1H-MRS) quantitative detection, and the liver fat content of the enrolled subjects was more than 5.5%. The subjects included in this study had either no history of alcohol consumption or their alcohol intake was less than 70 g/week in males and less than 140 g/week in females. Liver transaminase and serum creatinine were less than two times the upper limit of normal

Exclusion Criteria:

* T2DM complicated with ketoacidosis, hyperosmolarity, acute and chronic infection ● serious heart, liver, kidney, lung disease, and liver damage
* alcoholic fatty liver
* drug use that influences glucose metabolism such as thiazide diuretics and hormones within three months
* Hypertension ≥ 180/110 mmHg
* gastrointestinal disease or absorption dysfunction
* recent trauma, surgery, or other conditions resulting in an increased stress response within the past three months.
Olfactory Dysfunction of Rhinosinusitis

The purpose of this research is to improve understanding of the molecular and functional properties of the human olfactory system.

The specific aims are:

* to determine the location of AC3 and Golf proteins in the human olfactory epithelium from freshly harvested nasal/sinus tissue of surgical patients
* to perform objective functional studies on fresh human nasal/sinus tissue using an electro-olfactogram (EOG) whic measures the electrical activity of olfactory sensory neurons in fresh biopsied tissue in response to odor or pheromone stimulation. An organotypic culture system for human tissue has been established to optimize the electrical signal acquisition.
* to correlate the AC3 and Golf expression profiles with pre-operative testing of human olfactory function
* to correlate the EOG findings with pre-operative testing of human olfactory function.
* to systematically evaluate the role of individual intranasal agents on olfaction to further optimize the electrical signal acquisition from olfactory tissue.

This is a prospective cohort study. Subjects will be recruited from the group of patients at the University of Washington Otolaryngology-Head and Neck Surgery Clinic who will undergo endoscopic sinus surgery for chronic sinusitis and other disorders of the nasal cavity and sinuses.

Subjects will sign consent and complete a subjective smell test (UPSIT--University of Pennsylvania Smell Identification Test), and the SNOT-20 (Sinonasal Outcome Test-20)

During their surgery, subjects will have two to four pieces of normally discarded tissue preserved for the study. Subjects will also have two to four pieces of healthy tissue removed (total size approximately that of a pencil eraser tip)depending on the type of surgery involved. The following procedures will be performed on these tissues:

* immunocytochemistry utilizing antibodies to AC3 and Golf to determine the patterns and levels of expression of these proteins
* two odorants, isoamyl acetate and citralva, to elicit odorant-induced activity from the human olfactory sensory neurons. The tissue will also be subjected to two putative human pheromones: 4,16-androstadiene-3-ol and 1,3,5(10),16-estrateraen-3-ol.
* application of six commonly used intranasal agents: 0.9% saline, 1:1000,000 epinephrine, 0.05% oxymetazoline, 1% lidocaine, Zicam (0.12% zinc gluconate) and Nasocort AQ (triamcinolone acetate).

Eligibility Criteria:
Inclusion Criteria:

* over 18 yrs. of age, scheduled for: a.) endoscopic sinus surgery for chronic sinusitis, b.) endoscopic transnasal approach to the pituitary for pituitary tumor removal, c.) endoscopic inferior turbinectomy for nasal congestion d.)endoscopic repair of cerebrospinal fluid leaks

Exclusion Criteria:

* unable to give informed consent or complete questionnaires due to language, cognitive impairment or sever medical conditions.